Potential benefits of pentoxifylline on wound healing

Ahmadi, Motahareh; Khalili, Hossein

doi:10.1586/17512433.2016.1109443

Cited by 26 publications

(9 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, pentoxifylline may potentiate the action of pentavalent antimonials primarily by two mechanisms: increase in the expression of the inducible nitric oxide synthase (iNOS) and, consequently, increase in the production of nitric oxide, and anti-TNF- α action [86, 87]. Brito et al (2014) [88] observed that patients treated with pentoxifylline (400 mg - 3 times per day) combined with meglumine antimoniate (20 mg 5+ /kg/day) had greater TNF- α suppression than those treated with meglumine antimoniate alone (20 mg 5+ /kg/day), and cure rates were higher in the combined group than in the second group.…”

Section: Discussionmentioning

confidence: 99%

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review

Berbert

Mello

Nassif

et al. 2018

Dermatology Research and Practice

View full text Add to dashboard Cite

The first choice drugs for the treatment of cutaneous and mucocutaneous leishmaniasis are pentavalent antimonials, sodium stibogluconate, or meglumine antimoniate. However, the treatment with these drugs is expensive, can cause serious adverse effects, and is not always effective. The combination of two drugs by different routes or the combination of an alternative therapy with systemic therapy can increase the efficacy and decrease the collateral effects caused by the reference drugs. In this systematic review we investigated publications that described a combination of nonconventional treatment for cutaneous and mucocutaneous with pentavalent antimonials. A literature review was performed in the databases Web of Knowledge and PubMed in the period from 01st of December 2004 to 01st of June 2017, according to Prisma statement. Only clinical trials involving the treatment for cutaneous or mucocutaneous leishmaniasis, in English, and with available abstract were added. Other types of publications, such as reviews, case reports, comments to the editor, letters, interviews, guidelines, and errata, were excluded. Sixteen articles were selected and the pentavalent antimonials were administered in combination with pentoxifylline, granulocyte macrophage colony-stimulating factor, imiquimod, intralesional sodium stibogluconate, ketoconazole, silver-containing polyester dressing, lyophilized LEISH-F1 protein, cryotherapy, topical honey, and omeprazole. In general, the combined therapy resulted in high rates of clinical cure and when relapse or recurrence was reported, it was higher in the groups treated with pentavalent antimonials alone. The majority of the articles included in this review showed that cure rate ranged from 70 to 100% in patients treated with the combinations. Serious adverse effects were not observed in patients treated with drugs combination. The combination of other drugs or treatment modalities with pentavalent antimonials has proved to be effective for cutaneous and mucocutaneous leishmaniasis and for most seemed to be safe. However, new randomized, controlled, and multicentric clinical trials with more robust samples should be performed, especially the combination with immunomodulators.

show abstract

Section: Discussionmentioning

confidence: 99%

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review

Berbert

Mello

Nassif

et al. 2018

Dermatology Research and Practice

View full text Add to dashboard Cite

show abstract

“…There was a significant improvement in the vascularity of keloids only in group C. This can also be explained by synergistic effect between TAC and PTX as it is known that TAC injection can suppress VEGF 27 and PTX reduce PDGF (promoting neovascularization and blood vessel growth expression in keloid fibroblast). 28 Unfortunately, no statistically significant improvement in the pigmentation of keloids was detected in patients in any of the three studied groups.…”

Section: Discussionmentioning

confidence: 87%

Intralesional pentoxifylline, triamcinolone acetonide, and their combination for treatment of keloid scars

Serag-Eldin

Mahmoud

Gamea

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Keloids are fibroproliferative skin disorders that result from abnormal healing of irritated or injured skin. They contain inflammatory cells, newly formed blood vessels, fibroblasts in increased numbers, and excessive collagen deposits. 1 Their pathophysiology remains unknown but various mechanisms seem to be involved. There is now considerable evidence that keloidogenesis may be triggered by multiple systemic (e.g., adolescence, pregnancy, hypertension, and a variety of genetic and epigenetic factors) and local factors (e.g.,

show abstract

“…It enhances the resilience of erythrocytes besides boosts blood supply in the arteries. Following such improvements, blood circulation and oxygen supply was enhanced 25 .…”

Section: Pharmacological Actions Of Pentoxifyllinementioning

confidence: 99%

“…Prostacyclin and nitric oxide are documented for their strong vasodilator activity and inhibition of platelet aggregation. PTX further lowers blood viscosity through its fibrinolytic action 25 .…”

Section: Pharmacological Actions Of Pentoxifyllinementioning

confidence: 99%

The Use of Pentoxifylline Topical in the Treatment of Alopecia in Rats

Raad H. Hassan,

Ahmed H. Jwaid

2021

Indian Journal of Forensic Medicine & Toxicology

View full text Add to dashboard Cite

Hair is the human body's major esthetic display component, especially in cultural and social interactions. Hair loss is yet sometimes transient and the patient restore hair growth but have harmful effect on the psychology of the patient. Throughout this research, the potency of topical pentoxifylline (PTX) in stimulating regrowth in hair loss caused by cyclophosphamide was established. The study was performed by treated with PTX topically in male Swiss albino rats. The animals divided into seven groups with six animals in each group. To induce alopecia Cyclophosphamide used at a dose of (125 mg/kg) intraperitoneal. Macroscopically pentoxifylline (PTX) treated groups displayed new hair growth. Strong follicular proliferation was demonstrated by histopathology and gross morphological observations of hair growth in shaved areas. The blood biochemical cytokine assay revealed a down regulation of pro inflammatory TH1 cytokines TNF-α and INF-g, in addition there is up regulation of TH2 cytokine IL-13. In the study showed an efficient efficacy on the treatment of alopecia induced by cyclophosphamide.

show abstract

Potential benefits of pentoxifylline on wound healing

Cited by 26 publications

References 92 publications

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review

Intralesional pentoxifylline, triamcinolone acetonide, and their combination for treatment of keloid scars

The Use of Pentoxifylline Topical in the Treatment of Alopecia in Rats

Contact Info

Product

Resources

About